News
ALLO
3.480
+2.35%
0.080
Weekly Report: what happened at ALLO last week (0415-0419)?
Weekly Report · 1d ago
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Cathie Wood's fund ARK Invest invests in companies she expects to be the leaders of disruptive innovation. The fund is down 15% this year. Wood is a fan of investing in the companies of tomorrow. Her fund invests in the cutting-edge technologies of the day.
Benzinga · 5d ago
Weekly Report: what happened at ALLO last week (0408-0412)?
Weekly Report · 04/15 09:09
3 Meme Stocks to Sell and Replace With Meme Coins
Three meme stocks to sell include Rivian Automotive (RIVN), Tupperware Brands (TUP) and Allogene Therapeutics (ALLO) Social media has overshadowed the investing fundamentals, spotlighting meme stocks as prime candidates to sell. All three stocks are down 92% since November 2021.
Investorplace · 04/11 18:45
How Allogene (ALLO) Stock Stands Out in a Strong Industry
NASDAQ · 04/08 12:46
Weekly Report: what happened at ALLO last week (0401-0405)?
Weekly Report · 04/08 09:10
Showcasing Seeking Alpha's March 2024 New Analysts
Home Stock Ideas Quick Picks & Lists Showcasing Seeking Alpha's March 2024 New Analysts. There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. This month, we welcome the 24 analysts who published articles in March.
Seeking Alpha · 04/05 15:30
Weekly Report: what happened at ALLO last week (0325-0329)?
Weekly Report · 04/01 09:10
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024. The company's new 2024 platform vision will have a positive impact on the company's profitability. Allogene is a biotechnology company focused on the development of CAR-T cells for cancer treatment.
Seeking Alpha · 04/01 03:33
Weekly Report: what happened at ALLO last week (0318-0322)?
Weekly Report · 03/25 09:09
Stifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)
TipRanks · 03/20 02:05
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanks · 03/19 12:11
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
Benzinga · 03/19 10:55
Allogene Therapeutics: A Buy Rating on Strong Financials and Promising Clinical Prospects
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics (ALLO) with a price target of $10.00. The company develops a pipeline of genetically engineered T cell therapies for the treatment of cancer. Allogene has substantial cash reserves and is expected to sustain operations into 2026.
TipRanks · 03/19 10:27
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
TipRanks · 03/19 05:46
Weekly Report: what happened at ALLO last week (0311-0315)?
Weekly Report · 03/18 09:10
Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
TipRanks · 03/16 06:01
Allogene Therapeutics Price Target Maintained With a $10.00/Share by RBC Capital
Dow Jones · 03/15 16:29
RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
Benzinga · 03/15 16:19
Allogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel Therapy
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on Allogene Therapeutics. The company is developing a treatment for the treatment of large B-cell lymphoma. Allogene has been given a Buy rating by Cowen. The firm is developing genetically engineered allogeneic T cell therapies for cancer treatment.
TipRanks · 03/15 13:35
More
Webull provides a variety of real-time ALLO stock news. You can receive the latest news about Allogene Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.